Skip to main content
. 2014 Mar 18;33(6):1407–1414. doi: 10.3892/ijmm.2014.1703

Figure 6.

Figure 6

(A) Cell morphology in the control (healthy group), dysplasia model and miR-139-5p administration group shown by hematoxylin and eosin (H&E) staining (magnification, ×200). (B) Cell morphology in the control, dysplasia model and miR-139-5p administration group shown by Nissl staining.